Hims & Hers (HIMS) has caught a highly effective new tailwind, and the market is treating peptides as greater than a short-lived headline. The speedy catalyst was the FDA’s determination to carry a July 23-24 assembly of its Pharmacy Compounding Advisory Committee to assessment whether or not a number of peptides needs to be thought of for broader compounding entry.
The company’s agenda contains BPC-157, KPV, TB-500, MOTS-c, emideltide, Semax, and Epitalon. Reuters stated the FDA’s transfer helped ship Hims shares larger as buyers began pricing in a possible long-term opening for the class.
Reuters reported on April 16 that Hims shares rose greater than 7% after the FDA growth, whereas different market protection confirmed the rally constructing over a number of periods as buyers related the regulatory assessment to Hims’ current peptide ambitions.
The setup gave merchants a recent development narrative at a second when the corporate’s weight-loss enterprise is already being reworked round a broader mixture of authorised remedies.
Hims had already been constructing towards peptides
In February 2025, Hims introduced that it had acquired a California-based peptide facility, saying the deal would strengthen the long-term sturdiness of its home provide chain and help personalised medicines.
The corporate additionally stated the ability would assist it discover peptide innovation throughout preventive well being, metabolic optimization, cognitive efficiency, restoration science, and organic resistance.
Hims already has infrastructure tied to peptides, and the FDA assessment places a proper regulatory date on a enterprise line the corporate had been making ready for effectively earlier than this month’s rally. The market is now treating that preparation as an asset.
HIMS inventory has surged larger over 50% within the final 2 weeks
Cheng Xin by way of Getty Photographs
The GLP-1 reset left room for a brand new development story
The peptide angle is arriving at an essential time for Hims. In March, the corporate introduced a strategic shift in its U.S. weight-loss enterprise, saying it might align extra intently with Novo Nordisk and broaden entry to FDA-approved GLP-1 medicines whereas providing compounded semaglutide solely on a restricted scale. Just a few weeks later, Hims stated Novo’s FDA-approved GLP-1s had been out there via its platform.
Extra Well being
- Knowledgeable reveals which well being care prices are tax-deductible
- Medicare has an age hole that’s costing hundreds of thousands of People their well being
- Morgan Stanley names UnitedHealth a “Top Pick”
Compounded GLP-1s had been a significant a part of the corporate’s latest momentum, however shifting towards branded remedies raised new questions on future margin drivers and what class may carry the subsequent leg of development. Peptides now appear like the clearest reply buyers have discovered to this point.
The core enterprise was already rising quick
The market additionally has a powerful set of firm numbers beneath the peptide enthusiasm. In fourth-quarter and full-year 2025 outcomes, Hims reported fourth-quarter income of $617.8 million, up 28% 12 months over 12 months, and full-year income of $2.35 billion, up 59%.
The corporate reported 2.51 million subscribers at year-end, up 13%, together with $128.4 million in web earnings and $318.0 million in adjusted EBITDA for the total 12 months. Hims guided for 2026 income of $2.7 billion to $2.9 billion and adjusted EBITDA of $300 million to $375 million.
The corporate has additionally stored widening the platform. In February, Hims introduced an settlement to accumulate Eucalyptus, a digital-health firm with operations throughout Australia, the UK, Germany, Japan, and Canada. Administration stated the deal would assist speed up its effort to turn into a bigger international shopper well being platform.
Hims latest income
- Full-year 2025 income: $2.35 billion, up 59%
- Fourth-quarter 2025 income: $617.8 million, up 28%
- Full-year 2025 web earnings: $128.4 million
- Full-year 2025 adjusted EBITDA: $318.0 million
- Subscribers at year-end 2025: 2.51 million, up 13%
- 2026 income steering: $2.7 billion to $2.9 billion
- FDA peptide assessment dates: July 23-24, 2026
The market is buying and selling future optionality
The July FDA assembly continues to be solely a assessment step, and the committee’s suggestions are usually not the identical as a broad industrial inexperienced gentle. The company’s personal discover lays out a course of constructed round security, compounding guidelines, and technical assessment. The inventory is shifting on the likelihood that the end result may widen Hims’ future product menu, not on a brand new income stream that already exists at this time.
That also leaves a significant setup for buyers. Hims has a fast-growing core enterprise, a peptide facility already in place, a reshaped weight-loss technique, and a regulatory occasion that might open one other class with sturdy shopper curiosity. The rally displays a market that sees a brand new lane forming at precisely the second the corporate wanted one.
Associated: Hims & Hers shifts enterprise mannequin after Novo deal
